Deferoxamine Mesylate (2 brand names, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- DEFEROXAMINE MESYLATE
- DESFERAL
Dosage and Administration
The dosage (based on body weight in mg/kg/day), rates of administration, and mode of administration for both adults and pediatric patients are individually determined and adapted during the course of therapy based on the severity of the patient’s iron overload. The minimum daily dose of Deferoxamine Mesylate for Injection is 20 mg/kg/day for both adults and pediatric patients. The maximum daily dose is 40 mg/kg/day for pediatric patients and 60 mg/kg/day for adults.
Contraindications
Deferoxamine Mesylate for Injection is contraindicated in patients with: •A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see Description (11)]. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)]. •Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see Warnings and Precautions (5.3)].
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: •Hypersensitivity Reactions [see Warnings and Precautions (5.1)] •Auditory and Ocular Toxicity [see Warnings and Precautions (5.2)] •Renal Toxicity [see Warnings and Precautions (5.3)] •Respiratory Toxicity [see Warnings and Precautions (5.4)] •Growth Suppression [see Warnings and Precautions (5.5)] •Serious Infections [see Warnings and Precautions (5.6)] •Cardiac Dysfunction with Concomitant Use of Vitamin C [see Warnings and Precautions (5.7)] •Risks of Deferoxamine Mesylate for Injection Treatment in Patients with Aluminum Overload [see Warnings and Precautions (5.8)] •Effects on Ability to Drive and Use Machines [see Warnings and Precautions (5.9)]
Mechanism of Action
Deferoxamine Mesylate for Injection chelates iron by forming a stable complex that prevents the iron from entering into further chemical reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. Deferoxamine Mesylate for Injection does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100 parts by weight of Deferoxamine Mesylate for Injection is capable of binding approximately 8.5 parts by weight of ferric iron.